P-075 - PHARMACOKINETICS AND PHARMACODYNAMICS OF GS-1423, A FIRST-IN-CLASS BIFUNCTIONAL ANTIBODY TARGETING CD73 AND TGFΒ, IN SUBJECTS WITH ADVANCED TUMORS.

C. Hsueh¹, M. Zavodovskaya¹, T. Tarnowski¹, A. Tolcher², M. Gordon³, J. Strauss⁴, K. Mahoney⁵, J. Juergensmeier¹, T. Chen¹, A. Othman¹; ¹Gilead Sciences, Inc., Foster City, CA, USA, ²NEXT Oncology, San Antonio, TX, USA, ³HonorHealth Research Institute, Scottsdale, AZ, USA, ⁴Mary Crowley Research Center, Dallas, TX, USA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, USA.